Introduction
============

It is now well established that cells cross the feto--maternal interface in both directions with relative efficiency; maternal cells engraft in fetal tissue and vice versa \[[@ker430-B1], [@ker430-B2]\]. Persistence of the mother\'s cells in her offspring is termed maternal microchimerism (MMc), whereas persistence of fetal cells in the mother is termed fetal microchimerism (FMc). Both microchimeric states have persisted for decades \[[@ker430-B3], [@ker430-B4]\], but it is unclear what role these cells might have in health and disease. From an immunological perspective, it is intriguing that the engrafting fetal or maternal cells are tolerated despite sharing only 50% genetic identity with the surrounding cells. There are some clinical observations to suggest that these cells may play a role in susceptibility to autoimmune disease \[[@ker430-B5], [@ker430-B6]\], supporting the theories that (i) the initial trigger in autoimmunity may be alloimmune rather than autoimmune \[[@ker430-B7]\] or (ii) autoimmunity is associated with a breakdown in tolerance to microchimerism.

Some autoimmune diseases such as JDM and scleroderma share features with chronic graft *vs* host disease (cGvHD), a complication of bone marrow transplantation. Susceptibility to cGvHD is associated with incompatibility between the HLA genes expressed by the invading population from the donor and those of the recipient \[[@ker430-B8]\]. Given that most autoimmune diseases like JDM occur in subgroups of the population carrying certain HLA genes, it is reasonable to argue that HLA-incompatible alleles from the invading microchimeric population may cause a similar reaction in these genetically susceptible individuals. Indeed, there are now increasingly robust data supporting a role for microchimerism in JDM \[[@ker430-B9; @ker430-B10; @ker430-B11]\].

JDM is a multisystem autoimmune disease that results from inflammation of the small vessels of the muscle, skin, gastrointestinal tract and other organs. The incidence of JDM has been reported to be between 2 and 3/1 000 000 per year in children under 16 years of age \[[@ker430-B12]\], with an excess in females. Although significant progress has been made in the treatment of children with JDM, particularly using steroids, secondary effects can result in growth delay and osteopenia \[[@ker430-B13]\]. The underlying disease mechanisms are still poorly understood, but better understanding of the aetiology of the disease could lead to more targeted therapeutic strategies than broad-spectrum steroids. Involvement of the immune system in JDM has been demonstrated by the presence of lymphocytic and phagocytic infiltrates in muscle biopsies from children with JDM \[[@ker430-B14]\] and association with the HLA Class II allele *DQA1\*0501* \[[@ker430-B15]\]. Studies over the last decade investigated MMc in JDM: maternally derived chimeric cells were shown to be present more often in muscle biopsies from children with JDM compared with controls \[[@ker430-B9], [@ker430-B10]\]. Analysis of whole-blood DNA by quantitative polymerase chain reaction demonstrated increased MMc in children with JDM compared with their healthy siblings \[[@ker430-B10], [@ker430-B11], [@ker430-B16]\]. Further, in unrelated healthy offspring, the presence of chimerism was shown to be associated with HLA genotype of the mother, in particular HLA *DQA1\*0501* \[[@ker430-B16]\]. In the same study, experiments on peripheral blood lymphocytes showed that maternally derived microchimeric cells are activated when exposed to the JDM child\'s lymphocytes, indicating that MMc is immunologically active and may play a direct role in the disease process \[[@ker430-B16]\]. The aim of this project was to use state-of-the-art confocal imaging to determine whether MMc could be detected in muscle biopsies from children participating in the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland) (JDCBS).

Methods
=======

JDM tissue samples
------------------

A total of 220 children with JDM were recruited prospectively while 87 diagnosed children were recruited retrospectively to the JDCBS. Recruitment and structure of the study were as described \[[@ker430-B17]\]. As well as detailed clinical data, DNA, peripheral blood lymphocytes and muscle biopsies are stored for analysis. As JDM predominantly affects females, muscle biopsy sections were available from seven males with JDM to allow identification of maternal cells using X chromosome-specific FISH.

Control tissue samples
----------------------

Four control muscle sections were obtained: one from Professor Seth Love, Pathologist North Bristol Trust, from a 12-year-old boy with normal muscle pathology. The remaining three control sections were obtained from the JDCBS control cohort \[[@ker430-B18]\]. All three had been reported as normal by two independent expert pathologists. None of the four controls had any known muscle disease.

Ethical approval
----------------

Full written consent according to the Declaration of Helsinki was obtained for all samples (MREC/1/3/22) and appropriate local ethical approval was obtained for all tissues (National Research Ethics Service 04/Q2002/35).

Strategy
--------

Our approach was first to stain the X and Y chromosome using FISH and then to carry out concomitant IF to identify the antigen(s) of interest. MMc cells were identified, quantified and characterized using confocal microscopy.

FISH with concomitant IF
------------------------

Fresh frozen tissue sections of 7 μm (stored at −80°C) were fixed in acetone and air dried prior to a dehydration series. The FISH probes (Vysis CEP X Spectrum Orange/Y SpectrumGreen Direct Labelled Fluorescent DNA Probe, Abbott Molecular Inc., Des Plaines, IL, USA) were prepared according to the manufacturer\'s recommendation, and then applied on the tissue sections. DNA was denatured at 73°C for 10 min and then renatured with FISH probes by incubating overnight at 42°C. The following day, after post-hybridization washes, IF was started. Non-specific binding was blocked by incubating the slides with normal blocking serum for 60 min. Subsequently, slides were incubated with primary antibody (CD45-Mouse monoclonal; Dako UK Ltd, Ely, UK) for 4 h at 37°C, washed with 1× PBS/0.05% Tween-20, and then incubated with fluorescent secondary antibodies for 2 h at 37°C. For negative control slides, primary antibody was replaced by normal blocking serum. Sequential staining was performed for labelling double antigens. The sections were then dehydrated through an ethanol series, air dried and mounted with 4′,6-diamidino-2-phenylindole (DAPI) counterstain and mounting medium (Vector Laboratories, Inc., Burlingame, CA, USA).

Analysis
--------

All sections were analysed under a Leica SP5-AOBS confocal laser scanning microscope attached to a Leica DM I6000 inverted epifluorescence microscope. Images were taken by using a 63× magnification (oil) lens and 2× digital zoom. Cells were analysed by assigning them to one of four categories: X, Y, XY or XX. Video images are available. The FISH success rate (frequency of nuclei with both the X and Y chromosome observable) was determined in each sample. A Mann--Whitney non-parametric U-test was used to determine statistical differences in MMC frequency between the JDM and control groups.

Results
=======

MMc identification in JDM and control tissue
--------------------------------------------

MMc were identified by three colour fluorescence confocal imaging through individual nuclei as shown in [Fig. 1](#ker430-F1){ref-type="fig"}. More than 1000 cells were counted in each sample. The results obtained are shown in [Table 1](#ker430-T1){ref-type="table"}. F[ig]{.smallcaps}. 1Confocal imaging through a maternal cell (highlighted by arrow). The X chromosome is indicated by a red dot and the Y chromosome by a green dot. The nucleus is stained blue with DAPI. Imaging through this maternal cell, 2 X chromosomes (and no Y chromosomes) are observed. T[able]{.smallcaps} 1Subject characteristics, FISH success rate and MMc frequency in individuals with maternal microchimerism and controlsSampleAge at diagnosisAge at biopsyTotal cell countFISH success rate, %Number of MMc by confocal imagingMMc frequencyJDM 113 years 4 months13 years 5 months124284100.81JDM 29 years 11 months10 years 1 months105278121.14JDM 34 years 7 months4 years 9 months11138490.81JDM 45 years 8 months6 years 3 months236287100.42JDM 53 years 11 months4 years151880161.05JDM 62 years 10 months3 years 11 months112876100.89JDM 74 years 2 months4 years 3 months135787120.88Control 1NA12 years26188020.08Control 2NA5 years 8 months17817940.22Control 3NA5 years 7 months14207450.42Control 4NA2 years 5 months12877250.39[^3]

Analysis of MMc frequency in JDM and control tissue
---------------------------------------------------

MMc were identified in all tissues undergoing detailed examination ([Fig. 2](#ker430-F2){ref-type="fig"}). More than 1000 cells underwent analysis in each sample. The results obtained are shown in [Table 1](#ker430-T1){ref-type="table"}. Comparison of data between cases and controls showed a significant difference in MMc level (*P* = 0.01). F[ig]{.smallcaps}. 2Female (presumed maternal) cells identified in male JDM tissue from three JDM cases. The X chromosome is shown by a red dot, the Y chromosome by a green dot and the nucleus with DAPI (blue).

CD45 phenotyping
----------------

In order to establish whether maternal cells were of lymphoid origin, CD45 immunoflourescence with concomitant FISH was carried out on JDM sample 6 and control sample 2. As expected, CD45^+^ cells were observed more frequently in JDM tissue but no CD45^+^ MMc were identified ([Fig. 3](#ker430-F3){ref-type="fig"}). F[ig]{.smallcaps}. 3Maternal cells identified in JDM biopsies do not express CD45. FISH staining as in [Fig. 1](#ker430-F1){ref-type="fig"}. CD45^+^ lymphocytes (stained with FITC--green) were observed in JDM tissue, but no CD45^+^ MMc were observed.

Discussion
==========

Our analysis identified female (presumed maternal) cells in frozen muscle sections from seven males with well-characterized JDM using FISH. The frequency of MMc was higher in seven JDM muscle sections (0.42--1.14%) than in muscle sections from four controls (0.08--0.42%) (*P* = 0.01). These data, generated using state-of-the-art confocal imaging, validate and expand previous observations of increased frequency of MMc in male JDM tissue \[[@ker430-B9], [@ker430-B10]\]. This increase in frequency suggests a role for MMc in the pathogenetic mechanisms underlying JDM, yet proof of this role has been elusive. One theory suggests that these cells may be effector cells of the immune response, whereas another proposes that a frequency of MMc in tissue above a certain threshold could trigger an immune reaction.

To determine whether MMc in JDM muscle was lymphocytic in origin, the sections were co-stained with an antibody to CD45 that recognizes the human CD45 antigen, a tyrosine phosphatase also known as the leucocyte common antigen (LCA). CD45 is present in all human cells of haematopoietic origin, except erythroid cells, platelets and their precursor cells. While CD45^+^ host cells were identified and MMc was identified, no MMc co-stained positive for CD45. This supports recent data from Reed *et al*. \[[@ker430-B19]\] who did not identify CD45^+^ maternal cells. Further detailed characterization of maternal cells in JDM tissue is required to clarify the role of MMc in JDM. Work by the authors on the role of MMc in type 1 diabetes suggests that MMc in type 1 diabetes pancreas cells are tissue-specific insulin-producing β cells \[[@ker430-B20], [@ker430-B21]\] rather than cells of the immune system. Stevens *et al*. \[[@ker430-B22]\] showed that maternal cells constituted 0.017--1.9% of parenchymal cells and were found in liver, pancreas, lung, kidney, bladder, skin and spleen from seven male infant studies in detail. It is therefore possible that MMc plays different roles in different autoimmune diseases.

A strength of this study is the well-characterized JDM patient population from whom muscle biopsies were generally obtained shortly after diagnosis, but a weakness is that FISH is only useful to detect maternal cells in male biopsies with JDM. Improved strategies to detect MMc in female tissue are an important area for future development. The JDCBS represents a unique resource in that multiple tissue samples are available from each participant. It will therefore be possible to detect MMc levels in different tissues from the same individuals. One possibility is quantitative measurement of the non-inherited maternal antigen in peripheral blood samples that will require HLA genotyping of maternal DNA samples. This is likely to provide unique insights into the role of MMc in JDM.

Further characterization is required to address the role of MMc in JDM, in particular, phenotyping muscle microchimeric cells using a wide range of immunological, muscle and muscle stem cell markers to determine whether MMc in JDM are immune system or muscle derived. Another future aim is to use state-of-the-art laser capture technology to isolate and genotype these maternal cells and adjacent host cells to prove that the female cells in male tissue are maternal.
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